Enliven Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET.

The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event.

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being inhibitors to help patients with cancer live not only longer, but better.

Enliven Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer treatment, aiming to provide therapies that not only extend life but also improve quality of life for patients, with a particular focus on precision oncology approaches to address unmet needs in the field; headquartered in Boulder, Colorado, they utilize a discovery process combining validated biological targets with differentiated chemistry to design potentially first-in-class or best-in-class cancer therapies.

Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

Source: prnewswire.com

Report Abuse